Vitamin K epoxide reductase complex subunit 1 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Vitamin K epoxide reductase complex subunit 1 shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9BQB6. Start with Recurrent thrombophlebitis, then reuse UniProt Q9BQB6 as the stable protein anchor across project notes and exports.
Start with Recurrent thrombophlebitis, then reuse UniProt Q9BQB6 as the stable protein anchor across project notes and exports.
Vitamin K epoxide reductase complex subunit 1 shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.
Start review with Recurrent thrombophlebitis because it currently carries approved-linked support. Linked drugs include ACENOCOUMAROL, DICUMAROL, PHENINDIONE, PHENPROCOUMON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyVitamin K epoxide reductase complex subunit 1
Review this target as Vitamin K epoxide reductase complex subunit 1, mapped to UniProt Q9BQB6. Sequence length is 163 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Vitamin K epoxide reductase complex subunit 1 as ChEMBL target CHEMBL1930, mapped to UniProt Q9BQB6. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Vitamin K epoxide reductase complex subunit 1 is the right protein anchor across sources, using UniProt Q9BQB6 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Recurrent thrombophlebitis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Vitamin K epoxide reductase complex subunit 1 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q9BQB6 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Vitamin K epoxide reductase complex subunit 1 |
| UniProt Accession | Q9BQB6 |
| Component Type | Protein |
| Sequence Length | 163 aa |
Vitamin K epoxide reductase complex subunit 1
Review this target as Vitamin K epoxide reductase complex subunit 1, mapped to UniProt Q9BQB6. Sequence length is 163 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Vitamin K epoxide reductase complex subunit 1 shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block.
Start review with Recurrent thrombophlebitis because it currently carries approved-linked support. Linked drugs include ACENOCOUMAROL, DICUMAROL, PHENINDIONE, PHENPROCOUMON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4594145 | 8.35 | IC50 | 4.5 | Preclinical |
| CHEMBL1464 | 8.06 | IC50 | 8.8 | Approved |
| CHEMBL4530669 | 7.24 | IC50 | 58.2 | Preclinical |
| CHEMBL4517532 | 7.23 | IC50 | 59.0 | Preclinical |
| CHEMBL4443961 | 7.04 | IC50 | 90.2 | Preclinical |
| CHEMBL5435296 | 7.01 | IC50 | 98.0 | Preclinical |
| CHEMBL233451 | 6.82 | IC50 | 150.0 | Preclinical |
| CHEMBL5436380 | 6.3 | IC50 | 498.0 | Preclinical |
| CHEMBL5433796 | 6.28 | IC50 | 527.0 | Preclinical |
| CHEMBL5432023 | 6.19 | IC50 | 643.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell membrane format | 1 | 13 | 5.8 |
| cell-based format | 1 | 6 | 7.3 |
| single protein format | 1 | 4 | 4.2 |